---
title: "Macquarie: Raises JD HEALTH target price to HKD 74.57, maintains \"Outperform\" rating"
description: "Macquarie raised the target price for JD HEALTH by 20% to HKD 74.57, maintaining an \"Outperform\" rating. It is expected that revenue will grow by 22% year-on-year in the third quarter of 2025, and the"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/261543255.md"
published_at: "2025-10-17T03:24:03.000Z"
---

# Macquarie: Raises JD HEALTH target price to HKD 74.57, maintains "Outperform" rating

> Macquarie raised the target price for JD HEALTH by 20% to HKD 74.57, maintaining an "Outperform" rating. It is expected that revenue will grow by 22% year-on-year in the third quarter of 2025, and the adjusted net profit margin in the second half of the year will reach 8.1%, an increase of 90 basis points year-on-year. Macquarie believes that the company's position in the main healthcare product distribution channels will continue to strengthen, benefiting from the launch of new drugs and increased advertising spending, with an overall gross profit margin expected to expand by 1.5 percentage points year-on-year to 23.7%

According to the Zhitong Finance APP, Macquarie has released a research report stating that it has raised the target price for JD HEALTH (06618) by 20%, from HKD 62.14 to HKD 74.57, maintaining an "outperform" investment rating. Macquarie has kept its earnings forecast for the company unchanged. Macquarie expects that JD HEALTH will show a good trend in the third quarter of 2025, with a year-on-year revenue growth of 22% in the second half of the year. It is anticipated that under the weak performance of offline pharmacies, the company will continue to consolidate its position in the main healthcare product distribution channels, further increasing market share and integrating the market.

Macquarie expects the company to maintain strong growth momentum in the second half of the year, benefiting from the direct launch of more new drugs and stronger advertising spending from merchants. Macquarie predicts that the enhanced contribution from drug sales will impact the overall gross margin, believing that the growth rates of related categories (drugs > supplements > devices) will not show significant changes. It is believed that the company's supply chain capabilities and faster-growing market revenues can offset this drag and drive the group's gross margin to expand by 1.5 percentage points year-on-year to 23.7% in the second half of the year.

Considering the company's cautious approach to expanding offline stores and the increased spending during the promotional period in the fourth quarter, Macquarie expects the adjusted net profit margin in the second half of the year to reach 8.1%, a year-on-year increase of 90 basis points

### Related Stocks

- [06618.HK - JD HEALTH](https://longbridge.com/en/quote/06618.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 中國加強對在線票務平台的監管，重點打擊付費優先購買的行為 | 北京市市場監管局已對包括攜程和京東在內的 12 家主要在線票務平台進行了訪談，以解決在線火車票銷售中的不規範行為。監管機構已要求這些平台停止誤導性促銷，確保價格透明，同時打擊諸如虛假搶票等非法行為，以保護消費者權益 | [Link](https://longbridge.com/en/news/275689507.md) |
| 賣藥之外，京東健康的新敍事 | 在互聯網醫療經歷了數年的 “線上問診” 與 “醫藥電商” 的流量爭奪戰後，單純的線上流量紅利似乎已觸及天花板… | [Link](https://longbridge.com/en/news/273957053.md) |
| 京東深圳門店大受港客歡迎 包括體檢中心 京東 MALL 擬今年攻港 | 京東旗下深圳門店受到香港顧客的熱烈歡迎，計劃今年將京東 MALL 擴展至香港市場。港客在門店顧客中佔比達五、六成，尤其在咖啡機、健康體檢等領域表現突出。京東健康體檢中心的港客佔比高達 70%，每單體檢均價超過 2,000 元。為便利港人，京 | [Link](https://longbridge.com/en/news/273156059.md) |
| 市場監管總局約談阿里巴巴、抖音、百度、騰訊、京東、美團、淘寶閃購等平台企業 | 市場監管總局於 2 月 13 日約談了阿里巴巴、抖音、百度、騰訊、京東、美團和淘寶閃購等平台企業，要求它們遵守相關法律法規，落實主體責任，規範促銷行為，並杜絕 “內卷式” 競爭，以維護公平競爭市場環境，促進平台經濟的創新與健康發展。 | [Link](https://longbridge.com/en/news/275975190.md) |
| 2025 年的就業機會在哪裏？2026 年的就業機會將會在哪裏？ | 在 2025 年，職位增長微乎其微，只有教育和醫療保健（增加了 697,000 個職位）以及休閒和酒店業（增加了 119,000 個職位）顯示出顯著增長。其他行業，包括製造業和政府部門，經歷了下降。由於嬰兒潮一代的退休，失業率可能不會急劇上 | [Link](https://longbridge.com/en/news/275986113.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.